EUVIMEDEUVIMED entdecken
Validierungsstudie

Validation of a novel direct method to determine reduced adherence to atorvastatin therapy

Jonas Pivoriunas iD, Nils Tore Vethe iD, Einar Husebye iD, Morten W Fagerland iD, Stein Bergan iD, Oscar Kristiansen iD, John Munkhaugen iD, Elise Sverre iD

European Heart Journal - Cardiovascular Pharmacotherapy · 16.07.2024 · 10 (4) · 307-315

DOI: 10.1093/ehjcvp/pvae001 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 09.01.2024. Verfasst von Jonas Pivoriunas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Postboks 800, Drammen 3004, Norway. Hauptthemen laut MEDLINE: Atorvastatin, Medication Adherence, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Department of Medicine, Drammen Hospital, Vestre Viken Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Objective methods to determine statin adherence are requested to improve lipid management. We have recently established a method to detect reduced adherence to atorvastatin therapy with cut-off values based on the sum of atorvastatin and its major metabolites in the blood. We aimed to validate this method in patients with and without cardiovascular disease, and optimize previous cut-off values. Methods and results The pharmacokinetic study included 60 participants treated with atorvastatin 20 mg (N = 20), 40 mg (N = 20), and 80 mg (N = 20). Atorvastatin was then stopped and blood samples collected from day zero to day four. Quantification of the parent drug and its metabolites in blood plasma was performed with a liquid chromatography-tandem mass spectrometry assay. The cut-off values for reduced adherence were validated and optimized by calculating diagnostic sensitivity and specificity. Our candidate cut-off value of dose-normalized six-component sum of atorvastatin plus metabolites <0.10 nM/mg provided a sensitivity of 97% and a specificity of 93% for detecting ≥2 omitted doses. An optimized cut-off <0.062 nM/mg provided a sensitivity of 90% and a specificity of 100%. An alternative simplified two-component metabolite sum with a cut-off value <0.05 nM/mg provided a sensitivity of 98% and a specificity of 76%. An optimized cut-off <0.02 nM/mg provided a sensitivity of 97% and a specificity of 98%.

Conclusion

This validation study confirms that our direct method discriminates reduced adherence from adherence to atorvastatin therapy with high diagnostic accuracy. The method may improve lipid management in clinical practice and serve as a useful tool in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinMedication AdherenceHydroxymethylglutaryl-CoA Reductase InhibitorsHumansMaleFemaleMiddle AgedAgedHeptanoic AcidsPyrrolesTandem Mass SpectrometryChromatography, LiquidCardiovascular DiseasesReproducibility of ResultsDose-Response Relationship, Drug

Stichwörter der Autor:innen

AdherenceAtorvastatinLC-MS/MSLiquid chromatography-tandem mass spectrometryLow-density lipoprotein-cholesterol

Substanzen

AtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsHeptanoic AcidsPyrroles

Autor:innen und Institutionen

  • Department of Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Postboks 800, Drammen 3004, Norway.
  • Department of Behavioural Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Domus Medica, Sognsvannsveien 9, Oslo 0372, Norway.
  • Department of Pharmacology, Oslo University Hospital, Oslo 0372, Norway.
  • Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo 0372, Norway.
  • Oslo University Hospital, Ullevål Hospital, Oslo 0450, Norway.

ORCID-Profile: Jonas Pivoriunas, Nils Tore Vethe, Einar Husebye, Morten W Fagerland, Stein Bergan, Oscar Kristiansen, John Munkhaugen, Elise Sverre

Förderung

  • Department of Medicine, Drammen Hospital
  • Vestre Viken Trust

Zitieren

APA

Pivoriunas, J., Vethe, N. T., Husebye, E., Fagerland, M. W., Bergan, S., Kristiansen, O., Munkhaugen, J., & Sverre, E. (2024). Validation of a novel direct method to determine reduced adherence to atorvastatin therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 10(4), 307-315. https://doi.org/10.1093/ehjcvp/pvae001

Vancouver

Pivoriunas J, Vethe NT, Husebye E, Fagerland MW, Bergan S, Kristiansen O, et al. Validation of a novel direct method to determine reduced adherence to atorvastatin therapy. European Heart Journal - Cardiovascular Pharmacotherapy. 2024;10(4):307-315. doi:10.1093/ehjcvp/pvae001

BibTeX
@article{Pivoriunas2024,
  author = {Pivoriunas, Jonas and Vethe, Nils Tore and Husebye, Einar and Fagerland, Morten W and Bergan, Stein and Kristiansen, Oscar and Munkhaugen, John and Sverre, Elise},
  title = {Validation of a novel direct method to determine reduced adherence to atorvastatin therapy},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  volume = {10},
  number = {4},
  pages = {307--315},
  doi = {10.1093/ehjcvp/pvae001}
}
Kostenlos starten →